Given the superiority of ketamine as compared to memantine in treating some GRIN mutations (Li et al., 2016), and its widespread use in treating status epilepticus in adult and pediatric populations (Mewasingh et al., 2003; Ilvento et al., 2015; Zeiler, 2015), we sought to determine whether ketamine treatment was equally effective as memantine in abrogating GluN2A-P552R induced neurotoxicity in vitro. The gene discussed is GRIN2A; the disease is status epilepticus.